Literature DB >> 29331339

Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.

Laura Turco1, Guadalupe Garcia-Tsao2, Ilenia Magnani3, Marcello Bianchini1, Martina Costetti1, Cristian Caporali4, Stefano Colopi4, Emilio Simonini4, Nicola De Maria1, Federico Banchelli5, Rosario Rossi3, Erica Villa1, Filippo Schepis6.   

Abstract

BACKGROUND & AIMS: The main stages of cirrhosis (compensated and decompensated) have been sub-staged based on clinical, endoscopic, and portal pressure (determined by the hepatic venous pressure gradient [HVPG]) features. Vasodilation leading to a hyperdynamic circulatory state is central in the development of a late decompensated stage, with inflammation currently considered a key driver. We aimed to assess hepatic/systemic hemodynamics and inflammation (by C-reactive protein [CRP]) among the different sub-stages of cirrhosis and to investigate their interrelationship and prognostic relevance.
METHODS: A single center, prospective cohort of patients with cirrhosis undergoing per protocol hepatic and right-heart catheterization and CRP measurement, were classified into recently defined prognostic stages (PS) of compensated (PS1: HVPG ≥6 mmHg but <10 mmHg; PS2: HVPG ≥10 mmHg without gastroesophageal varices; PS3: patients with gastroesophageal varices) and decompensated (PS4: diuretic-responsive ascites; PS5: refractory ascites) disease. Cardiodynamic states based on cardiac index (L/min/m2) were created: relatively hypodynamic (<3.2), normodynamic (3.2-4.2) and hyperdynamic (>4.2).
RESULTS: Of 238 patients, 151 were compensated (PS1 = 25; PS2 = 36; PS3 = 90) and 87 were decompensated (PS4 = 48; PS5 = 39). Mean arterial pressure decreased progressively from PS1 to PS5, cardiac index increased progressively from PS1-to-PS4 but decreased in PS5. HVPG, model for end-stage liver disease (MELD), and CRP increased progressively from PS1-to-PS5. Among compensated patients, age, HVPG, relatively hypodynamic/hyperdynamic state and CRP were predictive of decompensation. Among patients with ascites, MELD, relatively hypodynamic/hyperdynamic state, post-capillary pulmonary hypertension, and CRP were independent predictors of death/liver transplant.
CONCLUSIONS: Our study demonstrates that, in addition to known parameters, cardiopulmonary hemodynamics and CRP are predictive of relevant outcomes, both in patients with compensated and decompensated cirrhosis. LAY
SUMMARY: There are two main stages in cirrhosis, compensated and decompensated, each with a main relevant outcome. In compensated cirrhosis the main relevant outcome is the development of ascites, while in decompensated cirrhosis it is death. Major roles of cardiac dysfunction and systemic inflammation have been hypothesized in the evolution of the disease in decompensated patients. In this study, we have shown that these factors were also involved in the progression from compensated to decompensated stage.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ascites; C-reactive protein; Cardiac index; Cirrhosis; HVPG; MELD; Survival

Mesh:

Substances:

Year:  2018        PMID: 29331339     DOI: 10.1016/j.jhep.2017.12.027

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  Small-diameter TIPS combined with splenic artery embolization in the management of refractory ascites in cirrhotic patients.

Authors:  Nathan E Frenk; Teodora Bochnakova; Suvranu Ganguli; Nathaniel Mercaldo; Andrew S Allegretti; Daniel S Pratt; Kei Yamada
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

Review 2.  Prophylactic Antibiotics in Cirrhosis: Are They Promoting or Preventing Infections?

Authors:  Guadalupe Garcia-Tsao
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

3.  CRP and the Prognosis of Patients with Cirrhosis.

Authors:  Nicoleta State
Journal:  Maedica (Bucur)       Date:  2021-09

Review 4.  Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?

Authors:  Anahita Rabiee; Guadalupe Garcia-Tsao; Elliot B Tapper
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-03-08

Review 5.  Portal pressure reductions induced by nonselective beta-blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites.

Authors:  Laura Turco; Guadalupe García-Tsao
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-06-03

6.  Future Pharmacological Therapies of Portal Hypertension.

Authors:  Guillermo A Ortiz; Guadalupe Garcia-Tsao
Journal:  Curr Hepatol Rep       Date:  2019-02-19

7.  Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.

Authors:  Lorenz Balcar; Marta Tonon; Georg Semmler; Valeria Calvino; Lukas Hartl; Simone Incicco; Mathias Jachs; David Bauer; Benedikt Silvester Hofer; Carmine Gabriele Gambino; Antonio Accetta; Alessandra Brocca; Michael Trauner; Mattias Mandorfer; Salvatore Piano; Thomas Reiberger
Journal:  JHEP Rep       Date:  2022-06-03

8.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

Review 9.  The Role of Anticoagulation in Treating Portal Hypertension.

Authors:  Laura Turco; Filippo Schepis; Erica Villa
Journal:  Curr Hepatol Rep       Date:  2018-06-18

Review 10.  Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.

Authors:  Cornelius Engelmann; Joan Clària; Gyongyi Szabo; Jaume Bosch; Mauro Bernardi
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.